医学
淋巴血管侵犯
阶段(地层学)
基底细胞
旁侵犯
放射治疗
回顾性队列研究
倾向得分匹配
端口(电路理论)
总体生存率
多元分析
癌症
外科
内科学
转移
工程类
古生物学
电气工程
生物
作者
Qiaoying Tian,Lin Jiang,Dongjun Dai,Lihong Liu,Xiaomeng Shi,Yinglu Guo,Dang Wu,Jia Yang,Jing Xu,Zhuoying Cai,Zhimin Ye,Yun Xi,Zengguang Zheng,Huimin Li,Yongjie Shui,Yanming Liu,Jinbiao Shang,Shumei Wei,Qichun Wei
摘要
PURPOSE To identify subgroups of patients with early-stage (pT1-2N0M0) oral tongue squamous cell carcinoma (OTSCC) who may benefit from postoperative radiotherapy (PORT). PATIENTS AND METHODS This retrospective cohort study included 528 patients diagnosed between October 2009 and December 2021. Clinicopathological characteristics and treatments with or without PORT were analyzed for their impact on outcomes. RESULTS Among 528 patients who underwent radical surgery (median age, 62 years [IQR, 52-69]), 145 (27.5%) also underwent PORT. Multivariate analyses revealed that PORT was associated with improved survival outcomes, whereas moderate-to-poor differentiation, perineural infiltration (PNI), lymphovascular invasion (LVI), and increasing depth of invasion (DOI) were associated with poorer survival outcomes. For patients with moderate-to-poor differentiation, the surgery + PORT group showed improved outcomes compared with the surgery-alone group. After propensity score matching, the results were as follows: overall survival (OS), 97% versus 69%, P = .003; disease-free survival (DFS), 88% versus 50%, P = .001. After excluding cases with PNI/LVI, the differences persisted: OS, 97% versus 82%, P = .040; DFS, 87% versus 64%, P = .012. Similar survival benefits were observed in 104 patients with PNI and/or LVI (OS, 81% v 58%; P = .022; DFS, 76% v 47%; P = .002). In subgroups with DOI >5 mm or close margins, PORT contributed to improved DFS (80% v 64%; P = .006; 92% v 66%; P = .049) but did not significantly affect OS. CONCLUSION Patients with moderately-to-poorly differentiated pT1-2N0M0 OTSCC benefited from PORT. Our study provided evidence that patients with PNI and/or LVI who underwent PORT had improved survival. PORT also offered DFS benefit among patients with DOI >5 mm.
科研通智能强力驱动
Strongly Powered by AbleSci AI